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Introduction
Mutations in the nucleophosmin gene (NPM1) are found in 30% of patients with acute myeloid leukaemia (AML) and lead to aberrant accumulation of nucleophosmin protein in the cytoplasm. 1 Distinctive biological and clinical features can be observed in NPM1 mutated AML, including a unique gene expression profile, a distinct microRNA signature, low expression of CD34 in more than 95% of cases, increased incidence of FLT3 internal tandem duplications (ITD) in about 40% of cases, and a good response to induction chemotherapy. [2] [3] [4] [5] NPM1 mutated AML was included as a provisional entity in the 2008 World Health
Organization classification of myeloid neoplasms. 6 Currently more than 40 different mutations in the NPM1 gene have been identified. 4 All these variants lead to common changes at the C-terminus of the gene and cause aberrant dislocation of the NPM1 protein into the cytoplasm of the AML blast cells. This feature of NPM1 mutated AML can be used for diagnostic purposes. Immunohistochemical staining of NPM1 on bone marrow biopsies has indeed been described to be fully predictive of NPM1 mutations by two independent research groups. 1;7;8 The low costs and relative simplicity are important advantages of immunohistochemistry in diagnostic screening, especially if more sophisticated molecular techniques are not available. On the other hand, compared to molecular analyses, immunohistochemistry is more prone to inter-observer variability and variability due to technical issues. Indeed, in the study of Konoplev et al. 9 immunohistochemical staining was not completely predictive for NPM1 mutations. Still, immunohistochemical staining is recommended as technique of choice in simple front-line screening, with a reported sensitivity and specificity of 100% on B5 fixed and EDTA decalcified bone marrow biopsies, and for diagnosis of AML patients presenting with "dry tap" or myeloid sarcoma. 10;11 In this study, we assessed the sensitivity and specificity of immunohistochemistry on formalin fixed bone marrow biopsies compared with gold standard molecular analysis to predict NPM1 mutation status in a large cohort of AML patients from our institution. The cases that were found to have a discrepancy between the two methods were extensively evaluated.
4
Methods
Patients
Bone marrow biopsies for immunohistochemical analysis and either peripheral blood or bone marrow aspirates for RNA isolation were obtained from untreated patients diagnosed with AML after achieving informed consent. The study protocol was approved by the Medical Ethical Committee of the University Medical Center Groningen.
Immunohistochemical staining for NPM1
The immunohistochemical stainings were performed on bone marrow biopsies that were fixed in 10% neutral phosphate buffered formalin (3.6% formaldehyde) for at least 12h, and Falini, Perugia, Italy). NPM1 was visualized using the ultraview universal DAB detection kit (Ventana). The nucleolin antigen was retrieved with a TRIS EDTA buffer (pH 9.0). The antinucleolin antibody (C23, Santa Cruz, Dallas, TX, USA) was used at a dilution of 1:50 and visualized using horse-radish peroxidase-labeled rabbit-anti-mouse and goat-anti-rabbit antibodies (Dako, Copenhagen, Denmark) and 3,3′-diaminobenzidine (Sigma Aldrich, St Louis, MO, USA). The NPM1 and nucleolin stainings were initially scored as being either exclusive nuclear or combined nuclear and cytoplasmic by an experienced hematopathologist (S.R., A.D. or P.M.K.).
Molecular analysis of NPM1
Molecular NPM1 mutation analysis was performed using RT-PCR of exon-12 harboring most NPM1 mutations. 4 Table 1 ). All qRT-PCR analyses were performed in triplicate and the mean expression of these triplicates is indicated in the results.
Fluorescence in situ hybridization (FISH)
Cytogenetic and FISH studies were performed according to standard methods. All discrepant Table 2 ).
13;14
Results
No complete concordance for immunohistochemical analysis on formalin fixed bone marrow biopsies and molecular analysis for the detection of NPM1 mutations
All cases with discordant results were further analyzed. Since mutations of exon 9 and 11 of the NPM1 gene have been described to occur in rare cases, 15;16 we performed additional sequencing analysis of exon 9, 11 and 12 for those 4 AML cases exhibiting cytoplasmic NPM1 by immunohistochemistry but no mutation by fragment analysis. This analysis did not reveal any mutations. Recently, a patient has been reported with mutated NPM1 detected by molecular analysis but predominant nuclear NPM1 by immunohistochemistry with a faint localization in the cytoplasm. 17 It was suggested that the amino acids at position 270 and 272 could be important for proper subcellular localization of NPM1. The types of NPM1 mutations found in our discrepant cases are depicted in Supplemental Table 2 . All these mutations were found in exon 12 of the NPM1 gene and did not resemble the mutation described by Pianta and colleagues.
Further analysis of the 5 discrepant cases included re-cutting tissue sections at 1-2 µm and microscopic analysis at 100x magnification. In 2 discordant cases with a proven mutation, blast cells again showed exclusively nuclear staining (cases 1 and 4 in Table 2 ; Figure 1 and Supplementary Figure 1) . In one case of AML with signs of differentiation (FAB M2) a minority of cells, probably the blasts, showed cytoplasmic staining (case 3), which had been overlooked in the original analysis of the thicker tissue sections. In an additional case with AML with multilineage dysplasia, previously classified as AML M6 (case 2), only small clusters of myeloblasts showed cytoplasmic staining. Finally the fifth discrepant case, a patient with unclassifiable AML (dry tap due to extensive sclerosis) and very few circulating blasts, the biopsy used for the original analysis showed only nuclear staining. However, a biopsy taken one day earlier in the referring hospital and only analyzed at re-analysis, showed convincingly cytoplasmic staining in apparently more blastic cells with larger nuclei and bigger nucleoli (case 5, Supplementary Figure 1) . Altogether, after re-analysis using 1-2 µm sections of the 5 discrepant cases with detectable mutations of NPM1 without cytoplasmic staining only 2 cases remained discrepant.
In the group of four discordant cases with cytoplasmic staining of NPM1 but no detectable mutation (case 6-9 in Table 2 ), cytoplasmic staining was very strong in one case (case 6) and fuzzy to granular in cases 8 and 9, whereas cytoplasmic staining of a very limited population of blasts was observed in case 7 ( 
NPM-MLF1 gene fusion detected in two out of four discrepant cases with cytoplasmic NPM1 but no detectable NPM1 mutation
Our analysis so far identified four AML cases (cases 6-9 in Table 2 ) with cytoplasmic NPM1
staining by immunohistochemistry, in the absence of an NPM1 mutation detected by molecular analysis. It has been described that cytoplasmic NPM1 staining can be observed in cases without a conventional NPM1 mutation, but in the presence of the rare chromosomal translocation t(3;5)(q25;q35) 23 . This translocation generates the chimeric gene named NPMmyelodysplasia/myeloid leukemia factor 1 (NPM-MLF1) encoding the NPM-MLF1 fusion protein 24 . The mechanism explaining the cytoplasmic NPM1 dislocation in these cases remains to be clarified. We tested the discrepant cases in our study demonstrating cytoplasmic NPM1 staining, but no NPM1 mutation for the NPM-MLF1 gene translocation by FISH using the RP11-117L6 and the TLX3 Break apart probe. This analysis revealed the presence of a break within the NPM1 gene highly suggestive for a NPM-MLF1 gene translocation in 2 out of 4 discrepant cases (cases 8 and 9 in Table 2 , Figure 3 ).
Discussion
The aim of this study was to evaluate the value of immunohistochemistry on formalin fixed bone marrow biopsies and molecular analysis for the detection of NPM1 mutations and further characterize the cases that were found to be discrepant between both techniques. We observed a high percentage of overlap between both methods of mutation detection.
Nevertheless, a small subgroup of patients could be identified with discordant results (5% in the studied cohort).
To analyze the possible effects of inter-observer variability in the use of immunohistochemistry, a cohort of 50 patients, including all cases that showed discordant results for the immunohistochemistry and fragment analysis, were re-scored blindly and independently by three hematopathologists and later discussed in a panel session. All nine cases remained discrepant after this procedure (data not shown).
Previously, Falini and colleagues reported 100% specificity and sensitivity of immunohistochemistry to detect mutated NPM1. 7 The superiority of their results might be explained by a difference in fixation technique, i.e. B5 fixation instead of formalin. The B5 fixation technique used for hematopoietic tissues is well known for its superior morphologic detail compared to formalin fixation. However, this technique has disadvantages, including difficulties with antigen retrieval for some antibodies (e.g. CD30, cyclin D1) and limitations to molecular studies. Moreover, the fixation can be problematic with respect to safety and disposal requirements in the laboratory, since B5 contains mercuric chloride. Therefore, currently, most pathology laboratories use purely formalin based fixation techniques, which provides a safe alternative. 25 In view of these considerations, all biopsies of the nine initially discordant cases were re-cut for thinner tissue sections and re-analyzed at higher magnification. Further, an additional biopsy taken in the referring hospital was included for re-analysis. In three of the five cases with initially nuclear staining but proven NPM1 mutations and a gene expression pattern characteristic for NPM1-mutated AML, we observed either a minor subpopulation with cytoplasmic staining or a discordance between two subsequent biopsies ( Table 2) . Only in two cases, the blasts were again scored as exclusively nuclear for NPM1 staining. This suggests that fixation and histotechnical factors may indeed contribute to the generation of false negative staining results. Differences in fixation, decalcification and staining procedures leading to difficulties in microscopic evaluation have also been addressed in previously published studies. 1;7-9;11 However, additional studies directly comparing different fixation techniques are necessary to assess the relevance of the fixation technique.
In addition to technical issues, characteristics of the AML blasts might also be important. We observed false negative results in an AML with myeloid maturation and one with a large component of erythroblasts. The cytoplasmic pattern of NPM1 is generally most prominent in myeloblasts and monoblasts as well as early erythroblasts. Indeed, cytoplasmic staining may be very weak or absent in more mature cells and might be below detection levels or more easily overlooked, especially in AML cases with M5b morphology. 26 Moreover, as is also illustrated by the results of this study, in rare cases only a very small population of blasts with cytoplasmic staining might be present.
Detection of mutant NPM1 could be improved by applying an antibody specific for mutant NPM1. Indeed, an NPM1-mutant specific antibody has been generated for the use in Western blot analysis. 27 However, to the best of our knowledge no such antibody is available for immunohistochemistry. Importantly, none of the cases with mutated NPM1 without overt cytoplasmic staining demonstrated the frameshift mutation, leading to a truncated protein, as has been described by Pianta et al. 17 Nevertheless, the reported truncated protein illustrates that not all identified NPM1 mutants are necessarily associated with overt cytoplasmic localization of NPM1.
The four cases with cytoplasmic NPM1 without detectable NPM1 mutation demonstrated the typical elevated expression of HOX and MEIS1 genes, which has been shown to be associated with NPM1 mutated AML, suggesting that these cases do not reflect regular NPM1 germline AML. Therefore it could be argued that immunohistochemistry should be applied to identify these rare, but interesting cases. Rare mutations in exon 9 and 11 of the NPM1 gene were excluded by sequencing. In two out of the four discrepant cases FISH analysis results were highly suggestive for the rare chromosomal translocation t(3;5)(q25;q35) encoding the NPM-MLF1 fusion protein. This finding is in line with a previous study describing aberrant cytoplasmic NPM1 localization in AML cases carrying a t(3;5). 23 In this study AML with t(3;5) was reported to account for only 0.25% of all adult AML aged 15-60. In our complete cohort of 119 cases, t(3;5) was found in 3% of all analyzed cases. case with strict nuclear staining of NPM1 and wild type NPM1 by fragment analysis; (B) case with nuclear and cytoplasmic staining of NPM1 and an NPM1 mutation by fragment analysis;
(C) discrepant case (case 1, Table 2 ) with strict nuclear staining but an NPM1 mutation found by fragment analysis; (D) discrepant case (case 2, Table 2 ) with a minor population of blasts with combined nuclear and cytoplasmic staining (black arrows) and many other cells with exclusively nuclear staining (orange arrows). The blasts with cytoplasmic expression had been overlooked at initial screening; (E) discrepant case (case 6, Table 2 ) with both nuclear and very strong cytoplasmic staining but no NPM1 mutation found by molecular analysis; (F) discrepant case (case 8, Table 2 ) with nuclear and cytoplasmic staining with a t(3;5)(q23;q3?3) likely involving NPM1. The inserts for cases 6 (panel E) and 8 (panel F) show the exclusively nuclear staining for the nucleolin protein as detected with the C23
antibody. All photographs were taken with a 100x oil immersion lens. Table 2 .
